IsoPSA clears FDA for biopsy risk

Prostate cancer screening has had a dumb problem for years. PSA blood tests catch some dangerous cancers early, but PSA also goes up for plenty of non-cancer reasons. So a lot of men end up in the gray zone — elevated PSA, no clear answer, and a biopsy decision that can feel like a coin flip. What changed in December 2025 is that the FDA gave Cleveland Diagnostics premarket approval for IsoPSA, a blood-based assay meant to sort that gray zone more intelligently. (targetedonc.com) ### What is IsoPSA actually measuring? IsoPSA is not just another total-PSA number. It looks at structural changes in PSA protein isoforms and runs that through an algorithm to estimate the likelihood that a biopsy would find clinically significant prostate cancer. Basically, the pitch is that c(targetedonc.com)ncer diagnosis. (accessdata.fda.gov) ### Who is it for? The FDA approval is pretty specific. IsoPSA is indicated as an aid in the decision for prostate biopsy in men age 50 and older who have elevated PSA levels. That wording matters. It is not for population-wide screening, and it is not a replacement for biopsy, MRI, or physician judgment. It sits earlier in t(accessdata.fda.gov)y the next invasive step? (targetedonc.com) ### Why does that narrow use case matter? Because biopsy is not a trivial follow-up. It is invasive, stressful, and can uncover low-grade disease that might never have caused harm, which then creates its own cascade of anxiety and treatment decisions. The whole value proposition here is fewer un(targetedonc.com)approval gives IsoPSA a different level of regulatory credibility than a lab-developed test alone. (targetedonc.com) ### What did the FDA clear, exactly? This was a Premarket Approval, or PMA, not a lighter-touch device pathway. The FDA database lists the device as the IsoPSA Assay, with Cleveland Diagnostics as the applicant, under PMA P200048. The approval was based on clinical evidence from a large prospect(targetedonc.com) technically reliable and that it helped with a real clinical decision. (accessdata.fda.gov) ### Why is Cleveland Diagnostics making a big deal about “kit” status? Because before this, IsoPSA was mainly offered as a lab-developed test through qualified high-complexity labs. With FDA approval of the in vitro diagnostic kit, Cleveland Diagnostics can supply the assay more broadly to clinical labs around the country. Th(accessdata.fda.gov)ifferently from a test kit other labs can adopt. (clevelanddx.com) ### Does this replace MRI or other reflex tests? No — and that is the catch people can miss. Urologists already use a mix of repeat PSA, percent free PSA, MRI, family history, age, digital rectal exam, and newer biomarkers to decide who gets biopsied. IsoPSA joins that crowded middle layer. Its success will depend less on the FDA headline and more on whether doctors find it (clevelanddx.com)rnatives already sitting in clinic workflows. That part is still a market adoption story. (targetedonc.com) ### Why are investors and diagnostics people paying attention? Because this is the kind of approval that can quietly change test distribution. Cleveland Diagnostics followed the approval by naming a new CEO and then a new chairman while talking openly about accelerated commercial growth. That su(targetedonc.com)cimen-handling vendors, a new FDA-approved kit can create downstream demand even if patients never hear the brand name. (businesswire.com) ### Bottom line? IsoPSA does not solve prostate cancer screening. But it does attack one of the messiest parts of it — the biopsy decision after an elevated PSA. If the test performs in everyday practice the way Cleveland Diagnostics says it did in the approval package, the win is simple: fewer men getting needles they did not need, and more confidence about who really should move forward. (targetedonc.com)